Urol. praxi. 2026;27(1):11-16 | DOI: 10.36290/uro.2025.035

Pharmacotherapy of overactive bladder syndrome and modern methods of treatment

MUDr. Jiří Sumara
Urologické oddělení Nemocnice Nové Město na Moravě, p. o.

The following text provides a detail overview of the current pharmacotherapy for OAB (overactive bladder), a review of individual anticholinergics, their properties, side effects, and an possible combinations of medicinal substances. A special attention is given to the treatment of OAB in older adults. Due to frequent presence of comorbidities and polypragmasia, it is advisable to administer antimuscarinics that have higher tissue selectivity and do not pass through the blood-brain barrier. In addition to pharmacological treatment, the text also discusses other modern therapeutic options such as the application of botulinum toxin, neurostimulation/modulation, and current perspectives of the future development and treatment options for OAB.

Keywords: overactive bladder, anticholinergics, antimuscarinic drugs, spasmolytics, combined treatment, botulinum toxin, neurostimulation, neuromodulation, n. saphenus, n. peroneus, surgery treatment.

Received: January 13, 2025; Revised: May 5, 2025; Accepted: May 8, 2025; Prepublished online: May 8, 2025; Published: March 16, 2026  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Sumara J. Pharmacotherapy of overactive bladder syndrome and modern methods of treatment. Urol. praxi. 2026;27(1):11-16. doi: 10.36290/uro.2025.035.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Purchase PDF - 60 CZK (2.5 EUR)
    will be unlocked 16.3.2027

    References

    1. Krhut J. Hyperaktivní močový měchýř. Maxdorf - Jessenius; 2007.
    2. Zachoval R, Krhut J, Záleský M, et al. Různé pohledy na problematiku hyperaktivního močového měchýře ze strany pacienta a ze strany lékaře - specialisty. Ces Urol. 2011;15(1):24-34. Go to original source...
    3. Hořčička L. Hyperaktivní močový měchýř. Kombinace léčby, anticholinergiky a beta3mimetiky. Urol. praxi. 2022;23(3): 117-119. Go to original source...
    4. Harding CK, Lapitan MC, Arlandis S, et al. EAU Guidelines in Management of Non-Neurogenic Female LUTS, EAU Guidelines; 2022.
    5. Grinstein E, Gluck O, Digesu A, et al. Update on non-invasive treatment for female overactive bladder. J Gynecol Obstet Hum Reprod. 2020;49(3):101683. Go to original source...
    6. Yamada S, Ito Y, Mishijima S, et al. Basic and clinical aspects of antimuscarinic agents used to treat overactive bladder. Pharmacol Ther. 2018;189:130-148. Go to original source...
    7. Ryšánková M. Perspektivy léčby syndromu hyperaktivního močového měchýře. Urol. praxi. 2019;20(3):102-107. Go to original source...
    8. Zámečník L. Moderní farmakoterapie v urologii. Praha: Max­dorf - Jesenius; 2019:187-211.
    9. Andersson KE. Antimuscarinic mechanism and the overactive detrusor: an update. Eur. Urol. 2011;59(3):377-386. Go to original source...
    10. Romžová M, Hurtová M, Pacovský J, et al. Inkontinence moče ve stáří. Urol. praxi. 2010;11(3):119-123.
    11. Chapple CHR, Yamanishi T, Chess-Williams R. Muscarinic receptor subtypes and management of overactive bladder. Urology. 2002;60(Suppl. 5A):82-89. Go to original source...
    12. Mašata J. Anticholinergní látky v léčbě hyperaktivního močového měchýře. Remedia. 2007;17:89-100.
    13. Verner P. Porovnání účinnosti a vedlejších účinků anticholinergik při léčbě OAB. Urol. praxi. 2010;11(5):241-246.
    14. EAU Guidelines Panel on Non-neurogenic Female LUTS. Management of Non-Neurogenic Female Lower Urinary Tract Symptoms (LUTS). Arnhem, The Netherlands: EAU Guidelines Office; 2021.
    15. Yarker YE, Goa KL, Fitton A. Oxybutynin: A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging. 1995;6(3):243-262. Go to original source...
    16. Davila GW. Transdermal oxybutynin in the treatment of overactive bladder. Clinical interventions in aging. 2006;1(2):99-105. Go to original source...
    17. Madersbacher H, Mürtz G, Alloussi S, et al. Propiverine vs. oxybutynin for treating neurogenic detrusor overactivity in children and adolescents: results of a multicentre observational cohort study. BJU Int. 2009;103(6):776-781. Go to original source...
    18. Madersbacher H, Ahnig L, Rettig K. Reizblasen symptomatik und Harndranginkontinenz - wirksame Therapie mit Spasmolyt - Dragees. Allgemeinarzt. 1995;17:501-503.
    19. Zachoval R. Fesoterodin, nové anticholinergikum pro léčbu hyperaktivního močového měchýře. Urol. Praxi. 2008;9(6)6:316-322.
    20. Zinner N, Tuttle J, Marks L. Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder. World J Urol. 2005;23(4):248-252. Go to original source...
    21. Drlík P. Nykturie - současné možnosti terapie. Urol. praxi. 2010;11(4):176-179.
    22. Aoki KR. Pharmacology and imunology of botulinum toxin type A serotype.Clin Dermatol. 2003;21:476-478. Go to original source...
    23. Haferkamp A, Schurch B, Reitz A, et al. Lack of ultrastructural detrusor changes following endoscopic injection of botulinum toxin type a in overactive neurogenic bladder. Eur Urol. 2004;46(6):784-791. Go to original source...
    24. Dykstra DD, Sidi AA, Scott AB, et.al. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol. 1988;139(5):919-922. Go to original source...
    25. Abdel-Meguid TA. Botulinum toxin A injections into the neurogenic overactive bladder to include or exclude the trigone. A prospective, randomized, controlled trial. J Urol. 2010;184(6):2423-2428. Go to original source...
    26. Krhut J, Zvara P. Intravesical instilation of botulinum toxin A: an in vivo murine study and pilot clinical trial. Int Urol Nep­hrol. 2011;43(2):337-343. Go to original source...
    27. Dressler D, Benecke R. Pharmacology of therapeutic botulinum toxin preparations. Disabil Rehabil. 2007;29(23): 1761-1768. Go to original source...
    28. Grosse J, Krammer G, Stohrer M. Success of repeat detrusor injection of botulinum A toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol. 2005;47(5):653-659. Go to original source...
    29. Krhut J, Mainer K. Stollerova aferentní stimulace v léčbě hyperaktivního měchýře - dvouleté zkušenosti. Urol praxi. 2001;5:204-206. Available from: https://www.urologiepropraxi.cz/pdfs/uro/2001/05/08.pdf.
    30. Stimvia získala prestižní MDR certifikaci zdra­vot­nického prostředku. [online], 13. 9. 2024. Medical Tribune Available from: https://­www.tribune.cz/medicina/stimvia-ziskala-prestizni-mdr-certi­fikaci-zdravotnickeho-prostredku/.
    31. Krhut J, Rejchrt M, Slovak M, et al. Prospective, randomized, multicenter trial of peroneal electrical transcutaneous neuromodulation vs solifenacin in treatment naive patients with overactive bladder. J Urol. 2023;209(4):734-741. Go to original source...
    32. Feloney MP, Stauss K, Leslie SW. Sacral Neuromodulation. Treasure Island (FL): StatPearls Publishing; 2025. Avai­lable from: https://www.ncbi.nlm.nih.gov/books/NBK567751/.
    33. Vrtal R, Vidlář A, Študent V. Diagnostika a léčba hyperaktivního měchýře. Urol. praxi. 2007;8(5):211-216.
    34. Song YS, Lee HY, Park JJ, et al. Persistence and adherence of anticholinergics and beta-3 agonist for the treat­ment of overactive bladder: systematic review and meta-analysis, and network meta-analysis. J Urol. 2021;205(6): 1526-1536. Go to original source...
    35. Pierre Fabre Laboratories announce granting of European marketing authorization for OBGEMSA (vibegron) in overactive bladder. News release. Pierre Fabre. June 28, 2024. Accessed July 1, 2024. https://www.prnewswire.com/news-releases/pierre-fabre-laboratories-announce-granting-of-european-marketing-authorization-for-obgemsa-vibegron-in-overactive-bladder-302185900.html.
    36. Marinkovic SP. New technologies in the management of overactive bladder: current research and future prospects. Ther Adv Urol. 2019;25;11:1756287219844669. Go to original source...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.